Predicting treatment outcomes for men with advanced prostate cancer using genetic information
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC
This study is looking to help men with advanced prostate cancer figure out if they will benefit from certain hormone therapies, so they can get the right treatment and avoid side effects from medications that might not work for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11009561 on NIH RePORTER |
What this research studies
This research aims to develop a clinical genomic predictive model to help determine which men with metastatic castration-resistant prostate cancer (mCRPC) will benefit from first-line androgen receptor inhibitor therapies like enzalutamide or abiraterone acetate. By analyzing genetic biomarkers, the study seeks to identify patients who are likely to experience durable benefits from these treatments, thereby optimizing therapy and minimizing unnecessary side effects for those unlikely to respond. The approach involves collecting and analyzing patient data to create a model that can guide treatment decisions. This could lead to more personalized and effective care for men facing this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who are considering first-line androgen receptor inhibitor therapies.
Not a fit: Patients who do not have metastatic castration-resistant prostate cancer or those who are not candidates for androgen receptor inhibitor therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for men with advanced prostate cancer by ensuring they receive the most effective therapies based on their genetic profiles.
How similar studies have performed: Previous research has shown promise in using genomic biomarkers to predict treatment responses in various cancers, suggesting that this approach could be effective in prostate cancer as well.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Halabi, Susan — Duke University
- Study coordinator: Halabi, Susan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.